Drug Discovery and Development

  • Home Drug Discovery and Development
  • Drug Discovery
  • Genomics/Proteomics
  • Oncology
  • Neurological Disease
  • Infectious Disease
  • R&D 100 Awards
  • Pharma 50
    • 2022 Pharma 50
    • 2021 Pharma 50

Lipidomics Research

By Drug Discovery Trends Editor | November 2, 2012

Agilent Technologies Inc. and Premier Biosoft announced that they will each support the combined use of their respective technologies to help clinical researchers advance lipidomics research. By integrating complementary technologies, researchers can seamlessly generate and process data, then map complex lipidomic networks to learn more about lipid metabolism associated with disease.

The power of Agilent’s industry-leading time-of-flight and quadrupole time-of-flight mass spectrometers and Pathway Architect software combined with Premier Biosoft’s SimLipid 3.3 identification and quantification software enables researchers to overcome many of the obstacles inherent in lipid identification and analysis. This will give them a distinct advantage in their efforts to map the lipid pathways associated with metabolic disease.

By connecting these complementary technologies, researchers can maximize the analytical capabilities of Agilent’s high-end MS instrumentation and software with Premier Biosoft high-throughput MS and MS/MS data analysis tools. SimLipid software supports data from Agilent’s well-known MassHunter, Mass Profiler Professional and Pathway Architect software programs, creating an integrated workflow for the accurate and efficient identification and contextualization of lipids on metabolic pathways.

Agilent Technologies Inc.


Filed Under: Drug Discovery

 

Related Articles Read More >

Takeda Pharmaceutical in the Drug Discovery & Development Pharma 50
Takeda’s Takhzyro fares well in pediatric hereditary angioedema study
Novartis in the Pharma 50
Novartis to cut up to 8,000 positions
Gilead Sciences in the Drug Discovery & Development Pharma 50
Gilead resubmits application to FDA for twice-yearly HIV drug lenacapavir
George Floyd mural
How the pandemic and George Floyd made clinical trial diversity a priority

MEDTECH 100 INDEX

Medtech 100 logo
Market Summary > Current Price
The MedTech 100 is a financial index calculated using the BIG100 companies covered in Medical Design and Outsourcing.

Need Drug Discovery news in a minute?

We Deliver!
Drug Discovery & Development Enewsletters get you caught up on all the mission critical news you need. Sign up today.
Enews Signup
Drug Discovery and Development
  • MASSDEVICE
  • DEVICETALKS
  • Medical Design & Outsourcing
  • MEDICAL TUBING + EXTRUSION
  • MEDTECH 100
  • Medical Design Sourcing
  • Subscribe to our Free E-Newsletter
  • Contact Us
  • About Us
  • Advertise With Us
  • R&D World
  • Drug Delivery Business News
  • Pharmaceutical Processing World

Copyright © 2022 WTWH Media LLC. All Rights Reserved. The material on this site may not be reproduced, distributed, transmitted, cached or otherwise used, except with the prior written permission of WTWH Media
Privacy Policy | Advertising | About Us

Search Drug Discovery & Development

  • Home Drug Discovery and Development
  • Drug Discovery
  • Genomics/Proteomics
  • Oncology
  • Neurological Disease
  • Infectious Disease
  • R&D 100 Awards
  • Pharma 50
    • 2022 Pharma 50
    • 2021 Pharma 50